Sugi Predict

Sugi Predict / Compounds / SCHEMBL521069

SCHEMBL521069

SCHEMBL521069

COC(=O)Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.57
▸ LMNA P02545 1/20 0.57
▸ CYP4F2 P78329 1/20 0.56
▸ CYP4A11 Q02928 1/20 0.56
▸ ALDH1A1 P00352 5/20 0.55
▸ MEN1 O00255 2/20 0.54
▸ HTT P42858 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ CYP1A2 P05177 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ PTGS2 P35354 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27874614 0.92 ALDH1A1 (0.55) MAPTLMNACYP4F2CYP4A11ALDH1A1
SCHEMBL24236050 0.89 BCL9 (0.55) MAPTLMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL9710536 0.85 ALDH1A1 (0.57) MAPTLMNAALDH1A1MEN1HTT
SCHEMBL7634110 0.84 ALDH1A1 (0.53) MAPTLMNAALDH1A1MEN1HTT
SCHEMBL398701 0.83 LMNA (0.73) MAPTLMNAALDH1A1MEN1HTT
SCHEMBL9710538 0.83 MAPT (0.55) MAPTLMNAALDH1A1MEN1HTT
SCHEMBL1350027 0.83 MAPT (0.57) MAPTALDH1A1MEN1KMT2APTGS2
SCHEMBL15522776 0.83 CYP4F2 (0.47) MAPTLMNACYP4F2CYP4A11ALDH1A1
SCHEMBL4113212 0.82 CYP4F2 (0.76) MAPTLMNACYP4F2CYP4A11ALDH1A1
SCHEMBL2441292 0.82 ALDH1A1 (0.57) MAPTLMNAALDH1A1MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109096134-A A kind of preparation method of equal amido phenenyl acid methyl esters 成家钢 2018-12-28 — — CN claimed
CN-106883166-A 4-（3- piperidyls）The preparation method of aniline and its tartrate 中国药科大学 2017-06-23 — — CN claimed
EP-4743082-A1 CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION UCL Business Ltd (GB) 2026-05-20 — — EP disclosed
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof LG CHEM, LTD. (KR) 2026-05-19 — — US disclosed
US-12552798-B2 Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) 2026-02-17 — — US disclosed
CN-120905185-A Mycobacterium hydrolase and application thereof in preparing essence and spice 江苏大学 2025-11-07 — — CN disclosed
US-20250340528-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-11-06 — — US disclosed
US-12459920-B2 Targeted protein degradation MONTE ROSA THERAPEUTICS AG (CH) 2025-11-04 — — US disclosed
US-20250243180-A1 TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS AG (CH) 2025-07-31 — — US disclosed
EP-4543856-A1 BENZOCARBAZOLE DERIVATIVES AS INHIBITORS OF DRP1 Asha Therapeutics LLC (US) 2025-04-30 — — EP disclosed
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-04-10 — — US disclosed
US-6610846-B1 Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide HOFFMAN-LA ROCHE INC. 2003-08-26 — — US disclosed
CN-1349519-A Glucokinase activators HOFFMANN LA ROCHE (CH) 2002-05-15 — — CN disclosed
EP-1169312-A2 GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-09 — — EP disclosed
US-6320050-B1 2-SUBSTITUTED PHENYL-3-CYCLOALKYL SUBSTITUTED N-HETEROAROMATIC PROPIONAMIDES; USED TO INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES. HOFFMANN-LA ROCHE INC. 2001-11-20 — — US disclosed
US-20010039344-A1 Heteroaromatic glucokinase activators HOFFMANN-LA ROCHE INC. 2001-11-08 — — US disclosed
WO-2001060781-A2 DIPHENYL COMPOUNDS, FORMULATIONS AND USES THEREOF UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2001-08-23 — — WO disclosed
WO-2000058293-A2 GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2000-10-05 — — WO disclosed
US-6124354-A TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME PHARMACIA & UPJOHN AB (SE) 2000-09-26 — — US disclosed
CN-1077953-A Acetogenin GLAXO GROUP LTD (GB) 1993-11-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115600-A1 COVALENT MODIFIERS OF AKT1 AND USES THEREOF AKT1, AKT1S1, AKT2 MAPT 3893/4885LMNA 2617/4885CYP4F2 4389/4885
US-20250243180-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MAPT 389/4885LMNA 1266/4885CYP4F2 4706/4885
US-12459920-B2 Targeted protein degradation NEK7, NEK1, RIPK1 MAPT 383/4885LMNA 1246/4885CYP4F2 4713/4885
US-12552798-B2 Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors BTK, LCK, SYK MAPT 3778/4885LMNA 4067/4885CYP4F2 2851/4885
US-20010039344-A1 Heteroaromatic glucokinase activators GCKR, GCK, PDXK MAPT 4402/4885LMNA 4339/4885CYP4F2 1329/4885
US-12630528-B2 Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof DGAT2, DGAT1, SOAT2 MAPT 4476/4885LMNA 3574/4885CYP4F2 566/4885
US-20250340528-A1 TARGETED PROTEIN DEGRADATION NEK7, NEK1, RIPK1 MAPT 389/4885LMNA 1266/4885CYP4F2 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.